Novavax, Inc. NVAX shares are trading higher in sympathy with Moderna Inc MRNA, which reported better-than-expected second-quarter results.
Quarterly revenue for Moderna was $4.75 billion compared to $4.34 million a year ago, beating the consensus of $4.07 billion.
Moderna has authorized an additional share repurchase program for $3 billion. The $3 billion repurchase program announced in February is continuing and currently has approximately $1 billion outstanding… Read More
According to data from Benzinga Pro, Novavax has a 52-week high of $277.80 and a 52-week low of $34.88.
Image and article originally from www.benzinga.com. Read the original article here.